Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

301 to 325 of 326 results

Final NICE “No” for Novartis’ Lucentis in diabetic macular edema treatment

30-11-2011

The National Institute for Health and Clinical Excellence (NICE), in final guidance issued today (November…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

UK’s NICE gives preliminary “no” to Novartis’ Lucentis for macular edema

24-11-2011

In preliminary recommendations published today (November) 24 by the UK drugs watchdog the National Institute…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

USA’s CMS to cover infusion costs associated with Dendreon’s Provenge

21-11-2011

Sales of Dendreon’s (Nasdaq: DNDN) new prostate cancer treatment Provenge (sipuleucel-T) have been…

BiotechnologyDendreonNorth AmericaOncologyPharmaceuticalPricingProvengeRegulation

UK’s NICE rejects Eisai’s Halaven for advanced breast cancer

17-11-2011

In a second negative from the UK’s National Institute for Health and Clinical Excellence, in final…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

UK’s NICE says no to AstraZeneca breast cancer drug Faslodex

10-11-2011

There was negative news this morning for Anglo-Swedish drug major AstraZeneca (LSE: AZN), when the UK’s…

AstraZenecaEuropeFaslodexOncologyPharmaceuticalPricingRegulation

UK NICE recommends Boehringer’s Pradaxa for stroke prevention

01-11-2011

In final draft guidance published today (November 1), the UK’s drug watchdog the National Institute…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

Australia’s GMiA completes Code review; comments on PBS cuts and vital role of pharma manufacturing

31-10-2011

Martin Cross, chairman of Australia’s Generic Medicines Industry Association (GMiA) has warned that…

Asia-PacificGenericsMarkets & MarketingPharmaceuticalPricingRegulation

Draft guidance from UK’s NICE recommends Roche’s RoActemra for systemic JIA

27-10-2011

In final draft guidance published today, by the UK drugs watchdog the National Institute for Health and…

Anti-Arthritics/RheumaticsEuropePharmaceuticalPricingRegulation

UK NICE draft guidance recommends Eli Lilly’s Bydureon for type 2 diabetes

18-10-2011

The UK drugs watchdog the National Institute of Health and Clinical Excellence (NICE) today published…

BydureonDiabetesEli LillyEuropePharmaceuticalPricingRegulation

UK’s NICE negative on Bristol-Myers skin cancer drug Yervoy

14-10-2011

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft…

Bristol-Myers SquibbEuropeOncologyPharmaceuticalPricingRegulationYervoy

UK’s NICE provisionally backs wider use of Roche’s RoActemra for rheumatoid arthritis

07-10-2011

The drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today opened…

Anti-Arthritics/RheumaticsPharmaceuticalPricingRegulationRoActemraRoche

AstraZeneca’s Brilique first to be assessed under Germany’s AMNOG, getting positive view

05-10-2011

The German reimbursement body, the Federal Joint Committee (G-BA), has published the Institute for Quality…

AstraZenecaBrilintaBriliqueCardio-vascularEuropePharmaceuticalPricingRegulation

Australian government U-turn on PBS listing of drugs

03-10-2011

More than 160,000 Australians per year will benefit from the Australian Government’s decision to…

Asia-PacificBoehringer IngelheimPharmaceuticalPradaxaPricingRegulation

Portuguese hospitals block access to new medicines as retail drug sector expected to meet savings goal

30-09-2011

Access to expensive medicines is becoming increasingly difficult in Portuguese public hospitals, while…

EuropeHealthcarePfizerPharmaceuticalPricingRare diseasesRegulationVyndaqel

SMC backs Celgene’s Vidaza for rare blood and bone marrow cancers in Scotland

12-09-2011

The Scottish Medicines Consortium (SMC), the equivalent of the UK’s drug watchdog the National Institute…

BiotechnologyCelgeneEuropeOncologyPharmaceuticalPricingRegulationVidaza

Draft guidance from UK's NICE recommends clinical trial for COPD drug Daxas

09-09-2011

New draft guidance from the UK's drug watchdog the National Institute for Health and Clinical Excellence…

DaxasEuropeMerck & CoNycomedPharmaceuticalPricingRegulationRespiratory and Pulmonary

Takeda’s Mepact backed by UK’s NICE for osteosarcoma, after previous negative opinion

07-09-2011

In a U-turn by the UK drug watchdog, in its latest appraisal, the National Institute for Health and Clinical…

EuropeMepactOncologyPharmaceuticalPricingRegulationTakeda Pharmaceuticals

Erbitux and Gilenya added to Australia’s PBS listing

02-09-2011

More than 400,000 Australians will benefit from new subsidized medicines, effective September 1, as Minister…

Asia-PacificErbituxGilenyaMerck KGaANeurologicalNovartisOncologyPharmaceuticalPricingRegulation

PCMA outlines $100 billion in Rx drug savings in USA

01-09-2011

As the USA’s Joint Select Committee on Deficit Reduction examines options to reduce the deficit…

BiotechnologyGenericsHealthcareNorth AmericaPharmaceuticalPricingRegulation

301 to 325 of 326 results

Back to top